Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Diagnósticos da América S.A. (DASA3.SA)
BRL2.66
+0.00 (+0.00%)
BR SAO Healthcare Medical - Diagnostics & Research
Address
Av. das Nações Unidas, 7815 05425-070
Barueri, SP, BR
Barueri, SP, BR
CEO
Lício Cintra
Website
dasa3.com.br
IPO
2004-11-19
ISIN BRDASAACNOR1
Description
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments. It also offers medical, property and vehicle rental, consultancy, and franchise contracting services. The company was formerly known as Laboratório Clínico Delboni Auriemo S.A. and changed its name to Diagnósticos da América S.A. in August 2000. Diagnósticos da América S.A. was founded in 1961 and is headquartered in São Paulo, Brazil.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
BRL2.66
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.33
Float Shares
830.14M
Free Float %
66.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.80% | -7.99% | -6.04% | -25.60% | +26.94% | -30.58% | +67.20% | -72.33% | -94.57% | -63.62% | -48.16% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.66
DCF (Unlevered)
2.81
+5.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
22% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 7 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.76
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-27.1% Q1'26: -41.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+4.2% Q1'26: +98.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-7.7% Q1'26: -4.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+9.1% Q1'26: +13.3% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+7.8% ★ Q1'26: +5.3% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.4% Q1'26: -2.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×4.14× Q1'26: 3.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 7 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.79B
est: 2.82B (-1.0%)
|
3.04B
est: 2.82B (+7.8%)
|
3.40B
est: 3.07B (+10.7%)
|
3.93B
est: 3.46B (+13.8%)
|
4.36B
est: 3.89B (+12.3%)
|
10.42B
est: 10.48B (-0.6%)
|
13.13B
est: 13.12B (+0.1%)
|
14.25B
est: 14.77B (-3.5%)
|
15.32B
est: 15.39B (-0.5%)
|
11.17B
est: 10.96B (+1.9%)
|
9.28B
9.23B – 9.32B
-15.3% YoY
|
9.97B
9.55B – 10.35B
+7.5% YoY
|
10.86B
10.81B – 10.91B
+8.9% YoY
|
| EBITDA |
452.16M
est: 389.15M (+16.2%)
|
634.95M
est: 389.15M (+63.2%)
|
627.16M
est: 423.31M (+48.2%)
|
612.70M
est: 476.55M (+28.6%)
|
879.03M
est: 536.20M (+63.9%)
|
1.08B
est: 1.45B (-25.4%)
|
2.21B
est: 1.81B (+22.2%)
|
2.21B
est: 2.24B (-1.4%)
|
2.15B
est: 2.34B (-7.9%)
|
2.14B
est: 1.66B (+28.5%)
|
1.41B
1.40B – 1.41B
-15.3% YoY
|
1.51B
1.45B – 1.57B
+7.5% YoY
|
1.65B
1.64B – 1.65B
+8.9% YoY
|
| EBIT |
254.27M
est: 127.95M (+98.7%)
|
385.86M
est: 127.95M (+201.6%)
|
399.30M
est: 139.18M (+186.9%)
|
352.90M
est: 156.68M (+125.2%)
|
412.00M
est: 176.30M (+133.7%)
|
148.92M
est: 475.14M (-68.7%)
|
1.10B
est: 594.94M (+84.7%)
|
911.78M
est: 897.45M (+1.6%)
|
784.32M
est: 935.36M (-16.1%)
|
1.01B
est: 665.76M (+52.1%)
|
563.65M
561.09M – 566.21M
-15.3% YoY
|
605.69M
580.17M – 628.97M
+7.5% YoY
|
659.64M
656.58M – 662.71M
+8.9% YoY
|
| Net Income |
23.81M
est: 224.87M (-89.4%)
|
94.74M
est: 224.87M (-57.9%)
|
131.44M
est: 849.50M (-84.5%)
|
184.38M
est: 1.15B (-84.0%)
|
124.78M
est: 1.25B (-90.0%)
|
-226.57M
est: 930.90M (-124.3%)
|
-386.92M
est: -422.00M (+8.3%)
|
-1.17B
est: -1.63B (+28.5%)
|
-1.20B
est: -627.45M (-91.1%)
|
-1.15B
est: -589.99M (-95.3%)
|
156.68M
151.93M – 161.43M
+126.6% YoY
|
437.83M
376.34M – 708.38M
+179.4% YoY
|
680.54M
665.38M – 690.03M
+55.4% YoY
|
| SGA |
211.38M
est: 400.60M (-47.2%)
|
224.66M
est: 400.60M (-43.9%)
|
332.44M
est: 435.77M (-23.7%)
|
452.88M
est: 490.58M (-7.7%)
|
455.14M
est: 551.99M (-17.5%)
|
1.08B
est: 1.49B (-27.5%)
|
1.20B
est: 1.86B (-35.8%)
|
2.98B
est: 2.44B (+22.2%)
|
3.19B
est: 2.54B (+25.5%)
|
2.38B
est: 1.81B (+31.8%)
|
1.53B
1.52B – 1.54B
-15.3% YoY
|
1.64B
1.57B – 1.71B
+7.5% YoY
|
1.79B
1.78B – 1.80B
+8.9% YoY
|
| EPS |
0.08
est: 0.18 (-56.7%)
|
0.31
est: 0.18 (+72.3%)
|
0.43
est: 0.68 (-36.8%)
|
0.59
est: 0.92 (-35.9%)
|
0.40
est: 1.00 (-60.1%)
|
-0.40
est: 0.75 (-153.7%)
|
-0.69
est: -0.34 (-104.3%)
|
-1.56
est: -1.30 (-19.9%)
|
-0.96
est: -0.50 (-91.8%)
|
-0.92
est: -0.39 (-136.5%)
|
0.13
0.12 – 0.13
+132.1% YoY
|
0.45
0.30 – 0.56
+260.0% YoY
|
0.54
0.53 – 0.55
+20.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.18B
OE per share TTM
-1.74
Owner's Yield
-56.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
44.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 6 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 22.2K | 0.56% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 24.9K | 0.44% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 69.5K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 94.5K | 0.39% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 86.3K | 0.28% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 15.8K | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
21.2K
Shares Outstanding
1.25B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andre Covre | Corporate Strategy Officer | — | male |
| Emerson Leandro Gasparetto | Chief Radiology & Imaging Diagnosis Officer and Member of Management Board | — | male |
| Fabio Sampaio De Lacerda | Vice President Director of People, Management & Culture | — | — |
| Fábio Ferreira Cunha | Chief Legal & Compliance Officer | — | male |
| Glauco Desiderio | Investor Relations Officer | — | male |
| Helisson Brigido Andrade Lemos | Vice President of Marketing and Products | — | — |
| Rafael Bossolani | Chief Financial & Investor Relations Officer | — | male |
| Rafael Lucchesi | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DASA3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
